GT201600263A - Ácidos grasos novedosos y su uso en la conjugación con biomoléculas - Google Patents

Ácidos grasos novedosos y su uso en la conjugación con biomoléculas

Info

Publication number
GT201600263A
GT201600263A GT201600263A GT201600263A GT201600263A GT 201600263 A GT201600263 A GT 201600263A GT 201600263 A GT201600263 A GT 201600263A GT 201600263 A GT201600263 A GT 201600263A GT 201600263 A GT201600263 A GT 201600263A
Authority
GT
Guatemala
Prior art keywords
diseases
disease
metabolic
gdf15
conjugate
Prior art date
Application number
GT201600263A
Other languages
English (en)
Inventor
David Weninger Barnes
Ken Yamada
Chikwendu Ibebunjo
Alokesh Duttaroy
Louise Clare Kirman
Alexandra Marshall Bruce
Aimee Richardson Usera
Frederic Zecri
Jun Yuan
Changgang Lou
Aaron Kanter
Avirup Bose
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53491695&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201600263(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of GT201600263A publication Critical patent/GT201600263A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/22—Tricarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/18—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon triple bonds as unsaturation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/285—Polyhydroxy dicarboxylic acids having five or more carbon atoms, e.g. saccharic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

LA INVENCIÓN SE REFIERE A NOVEDOSOS CONJUGADOS DE GDF15, LOS CUALES TIENEN UNA MEJOR VIDA MEDIA Y DURACIÓN DE ACCIÓN. LA INVENCIÓN TAMBIÉN SE REFIERE A UN MÉTODO PARA LA ELABORACIÓN DEL CONJUGADO DE LA INVENCIÓN TAL COMO EL CONJUGADO DE GDF15, Y A SUS USOS TERAPÉUTICOS TALES COMO EL TRATAMIENTO O LA PREVENCIÓN DE TRASTORNOS O ENFERMEDADES METABÓLICAS, DIABETES MELLITUS TIPO 2, OBESIDAD PANCREATITIS, DISLIPIDEMIA, ENFERMEDAD DE HÍGADO GRASO ALCOHÓLICO Y NO ALCOHÓLICO/ESTEATOHEPATITIS Y OTRAS ENFERMEDADES PROGRESIVAS DEL HÍGADO, RESISTENCIA A LA INSULINA, HIPERINSULINEMIA, INTOLERANCIA A LA GLUCOSA, HIPERGLUCEMIA, SÍNDROME METABÓLICO, HIPERTENSIÓN, ENFERMEDAD CARDIOVASCULAR, ATEROESCLEROSIS, ENFERMEDAD DE ARTERIAS PERIFÉRICAS, EMBOLIA, INSUFICIENCIA CARDÍACA, ENFERMEDAD CARDÍACA CORONARIA, COMPLICACIONES DIABÉTICAS (INCLUYENDO, PERO NO LIMITÁNDOSE A, ENFERMEDAD CRÓNICA DEL RIÑÓN), NEUROPATÍA, GASTROPARESIS Y OTROS TRASTORNOS METABÓLICOS. LA PRESENTE INVENCIÓN PROPORCIONA ADEMÁS UNA COMBINACIÓN DE LOS AGENTES FARMACOLÓGICAMENTE ACTIVOS Y UNA COMPOSICIÓN FARMACÉUTICA.
GT201600263A 2014-06-23 2016-12-22 Ácidos grasos novedosos y su uso en la conjugación con biomoléculas GT201600263A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462015862P 2014-06-23 2014-06-23
US201462082327P 2014-11-20 2014-11-20
US201562107016P 2015-01-23 2015-01-23

Publications (1)

Publication Number Publication Date
GT201600263A true GT201600263A (es) 2019-07-19

Family

ID=53491695

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201600263A GT201600263A (es) 2014-06-23 2016-12-22 Ácidos grasos novedosos y su uso en la conjugación con biomoléculas

Country Status (37)

Country Link
US (4) US10588980B2 (es)
EP (2) EP3157571B1 (es)
JP (5) JP6636959B2 (es)
KR (2) KR102559975B1 (es)
CN (3) CN107073130B (es)
AP (1) AP2016009585A0 (es)
AU (1) AU2015280351C1 (es)
CA (1) CA2953480A1 (es)
CL (1) CL2016003281A1 (es)
CR (1) CR20160596A (es)
CU (1) CU24455B1 (es)
CY (1) CY1125006T1 (es)
DK (1) DK3157571T3 (es)
EA (1) EA039074B1 (es)
EC (1) ECSP17004665A (es)
ES (1) ES2905479T3 (es)
GT (1) GT201600263A (es)
HK (1) HK1232160A1 (es)
HR (1) HRP20220152T1 (es)
HU (1) HUE057845T2 (es)
IL (1) IL248990B (es)
JO (1) JO3813B1 (es)
LT (1) LT3157571T (es)
MA (1) MA40278A (es)
MX (1) MX367520B (es)
MY (1) MY193993A (es)
PE (1) PE20171095A1 (es)
PH (1) PH12016502294A1 (es)
PL (1) PL3157571T3 (es)
PT (1) PT3157571T (es)
RS (1) RS62907B1 (es)
SG (2) SG10201912965TA (es)
SI (1) SI3157571T1 (es)
TN (1) TN2016000558A1 (es)
TW (3) TWI701048B (es)
UY (1) UY36186A (es)
WO (1) WO2015200078A1 (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8420088B2 (en) 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
CA2832581C (en) 2011-04-08 2022-08-23 Yumei Xiong Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
AU2014296107B2 (en) 2013-07-31 2018-07-26 Amgen Inc. Growth differentiation factor 15 (GDF-15) constructs
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
AU2015356643B2 (en) 2014-12-04 2019-01-24 Novartis Ag Methods and compositions using Klotho variant polypeptides
AU2016209968B2 (en) 2015-01-23 2018-11-29 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
JP6946304B2 (ja) 2015-12-22 2021-10-06 ノバルティス アーゲー 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法
EP3408391A4 (en) 2016-01-31 2019-08-28 University of Massachusetts BRANCHED OLIGONUCLEOTIDES
MA45113A (fr) 2016-05-24 2019-04-10 Novo Nordisk As Composés mic-1 et leur utilisation
KR101727506B1 (ko) * 2016-07-14 2017-05-04 충남대학교 산학협력단 Gdf15 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 유효성분으로 함유하는 지방간의 예방 또는 치료용 약학적 조성물
WO2018031933A2 (en) * 2016-08-12 2018-02-15 University Of Massachusetts Conjugated oligonucleotides
RU2021133626A (ru) 2017-01-23 2022-01-31 Регенерон Фармасьютикалз, Инк. Варианты hsd17b13 и их применения
ES2963839T3 (es) 2017-02-08 2024-04-02 Bristol Myers Squibb Co Polipéptidos de relaxina modificados que comprenden un potenciador farmacocinético y usos de los mismos
KR20190139869A (ko) 2017-04-11 2019-12-18 리제너론 파마슈티칼스 인코포레이티드 하이드록시스테로이드 (17-베타) 탈수소효소(hsd17b) 패밀리의 구성원의 조절인자의 활성도를 스크리닝하기 위한 검정
US20180334426A1 (en) * 2017-05-18 2018-11-22 Regeneron Pharmaceutical, Inc. Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
TWI710377B (zh) * 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
JP7434151B2 (ja) 2017-10-11 2024-02-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｐｎｐｌａ３ ｉ１４８ｍの変異を発現している患者の肝疾患の治療におけるｈｓｄ１７ｂ１３の阻害
CN111601613A (zh) * 2017-12-22 2020-08-28 诺华股份有限公司 用fgf21变体治疗代谢障碍的方法
WO2019179494A1 (zh) * 2018-03-23 2019-09-26 深圳市塔吉瑞生物医药有限公司 取代的十五烷二酸化合物及药物组合物及其用途
PE20201350A1 (es) 2018-04-09 2020-11-30 Amgen Inc Proteinas de fusion del factor de diferenciacion de crecimiento 15
JP7398396B2 (ja) 2018-06-01 2023-12-14 ノバルティス アーゲー Ｂｃｍａに対する結合分子及びその使用
MX2021001590A (es) 2018-08-10 2021-07-02 Univ Massachusetts Oligonucleótidos modificados dirigidos a snp.
KR20210044244A (ko) 2018-08-10 2021-04-22 노파르티스 아게 Gfral 세포외 도메인 및 사용 방법
TW202023573A (zh) * 2018-09-19 2020-07-01 美商Ionis製藥公司 Pnpla3表現之調節劑
SG11202103990QA (en) * 2018-10-22 2021-05-28 Janssen Pharmaceutica Nv Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof
US20220025344A1 (en) 2018-11-26 2022-01-27 Novartis Ag Lpl-gpihbp1 fusion polypeptides
CN113767112A (zh) * 2019-04-23 2021-12-07 株式会社Lg化学 包含免疫球蛋白Fc区和GDF15的融合多肽
CN111909256A (zh) * 2019-05-10 2020-11-10 宁波鲲鹏生物科技有限公司 多肽衍生物及其制备方法
AU2020279974A1 (en) 2019-05-21 2021-11-18 Novartis Ag CD19 binding molecules and uses thereof
WO2020236797A1 (en) 2019-05-21 2020-11-26 Novartis Ag Variant cd58 domains and uses thereof
EP3999103A4 (en) * 2019-07-19 2023-11-22 Inari Agriculture Technology, Inc. GENOMIC EDITING FOR ENHANCED HOMOLOGY-DIRECTED REPAIR
BR112022002307A2 (pt) 2019-08-09 2022-06-28 Univ Massachusetts Oligonucleotídeos quimicamente modificados que têm como alvo snps
WO2021067655A1 (en) 2019-10-04 2021-04-08 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
WO2021089554A1 (en) 2019-11-04 2021-05-14 Ferring B.V. Intranasal administration of merotocin for improving lactation
MX2022006097A (es) * 2019-11-26 2022-10-18 Dtx Pharma Inc Compuesto que comprende un acido nucleico y un motivo de extension de la vida media.
WO2021126990A1 (en) * 2019-12-16 2021-06-24 The Scripps Research Institute Oxytocin derivatives with improved properties
CN113597434B (zh) 2019-12-31 2022-07-01 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
WO2021144313A1 (en) * 2020-01-13 2021-07-22 Synaffix B.V. Via cycloaddition bilaterally functionalized antibodies
WO2021144314A1 (en) * 2020-01-13 2021-07-22 Synaffix B.V. Via cycloaddition bilaterally functionalized antibodies
JP2023509991A (ja) * 2020-01-13 2023-03-10 シンアフィックス ビー．ブイ． 抗体及び免疫細胞エンゲージャーのコンジュゲート
EP4240491A1 (en) 2020-11-06 2023-09-13 Novartis AG Cd19 binding molecules and uses thereof
KR102543789B1 (ko) * 2021-03-08 2023-06-20 주식회사 온코크로스 토르세미드 및 크로몰린을 포함하는 대사질환 예방 또는 치료용 조성물
WO2022219495A1 (en) 2021-04-12 2022-10-20 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
TW202304500A (zh) 2021-04-21 2023-02-01 瑞士商諾華公司 升糖素樣肽化合物
WO2022245183A1 (en) * 2021-05-21 2022-11-24 Yuhan Corporation Composition for preventing or treating non-alcoholic fatty liver disease or non-alcoholic steatohepatitis comprising growth differentiation factor-15 variant
JP2024523509A (ja) 2021-06-23 2024-06-28 ユニバーシティー オブ マサチューセッツ 子癇前症及び他の血管新生障害の治療のために最適化された抗ｆｌｔ１オリゴヌクレオチド化合物
CA3231700A1 (en) * 2021-09-10 2023-03-16 Guardian Therapeutics, Llc Fatty acid conjugates of nucleic acids
CN113582832B (zh) * 2021-09-13 2024-01-26 深圳瑞德林生物技术有限公司 一种长链二酸的制备方法
WO2023152698A1 (en) 2022-02-10 2023-08-17 Novartis Ag 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases
CN114740105B (zh) * 2022-03-17 2023-11-07 重庆医药高等专科学校 一种脯氨酸和n-甲基脯氨酸的液相色谱分离检测方法及其应用
WO2023196754A2 (en) * 2022-04-08 2023-10-12 University Of North Texas Health Science Center At Fort Worth Treatment for reducing or preventing tissue fibrosis
CN114891086B (zh) * 2022-06-01 2024-03-26 恺佧生物科技(上海)有限公司 一种生物素标记的gdf15的复性方法
WO2024030367A2 (en) * 2022-08-01 2024-02-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Fatty acid-d-amino acid peptides conjugates as anaplerotic compounds for use in treating propionic acidemia, methylmalonic acidurias, and energy metabolic disorders
CN116466010B (zh) * 2023-06-15 2023-08-25 四川普锐特药业有限公司 一种用于脂质纳米粒中多种脂质组分定量检测的方法

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3043871A (en) * 1956-09-03 1962-07-10 Ruhrchemie Ag Production of heptadecanedicarboxylic acid-1, 17
WO1983004412A1 (en) 1982-06-11 1983-12-22 National Research Development Corporation Amphipathic compounds
US4517105A (en) 1983-03-07 1985-05-14 Aluminum Company Of America Metalworking lubricant composition containing a novel substituted malonic acid diester
US4582927A (en) 1984-04-04 1986-04-15 Frito-Lay, Inc. Synthetic cooking oils containing dicarboxylic acid esters
US5175191A (en) 1988-11-14 1992-12-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
DE69120645T2 (de) 1990-12-26 1997-02-13 Ricoh Kk Reversible wärmeempfindliche Aufzeichnungszusammensetzung, Aufzeichnungsmedium, Aufzeichnungsverfahren und Anzeigevorrichtung, die das Aufzeichnungsmedium verwendet
US6521227B1 (en) 1999-11-18 2003-02-18 Peter L. Hudson Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
US5994102A (en) 1994-12-15 1999-11-30 Human Genome Sciences, Inc. Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
AU1830195A (en) 1994-12-15 1996-07-03 Human Genome Sciences, Inc. Prostatic growth factor
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
FR2735131B1 (fr) 1995-06-12 1997-08-22 Rech De Pathologie Appliquee S Conjugues d'msh avec un acide gras, leur procede de preparation et leur utilisation a titre de medicament
EP0833912B1 (en) 1995-06-22 2009-02-25 St Vincent's Hospital Sydney Limited Novel tgf-beta like cytokine
US20020052310A1 (en) 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
JP2001500732A (ja) 1996-09-11 2001-01-23 オーソ―マクニール・フアーマシユーチカル・インコーポレーテツド 前立腺がんを治療するためのＴＮＦ―β様タンパク質、ならびに関連する核酸分子、医薬組成物および方法
AU8591198A (en) 1997-07-31 1999-02-22 Johns Hopkins University School Of Medicine, The Growth differentiation factor-15
ATE383424T1 (de) 1997-12-24 2008-01-15 Takeda Pharmaceutical Polypeptide, deren herstellung und verwendung
US6974684B2 (en) 2001-08-08 2005-12-13 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US6297400B1 (en) 1999-07-02 2001-10-02 The Clorox Company Synthesis of a tetraamido macrocycle ligand from a novel diamidodiol
WO2001077288A2 (en) 2000-04-06 2001-10-18 Genetics Institute, Llc. Polynucleotides encoding novel secreted proteins
CA2405680C (en) 2000-04-20 2018-02-13 St. Vincent's Hospital Sydney Limited Diagnostic assay and method of treatment involving macrophage inhibitory cytokine -1 (mic-1)
DK2128246T3 (da) 2001-04-19 2014-05-12 Univ California Fremgangsmåder og sammensætninger til fremstilling af ortogonale tRNA-aminoacyl-tRNA-syntetasepar.
US20030166903A1 (en) 2001-04-27 2003-09-04 Anna Astromoff Genes associated with vascular disease
KR100913714B1 (ko) 2001-11-08 2009-08-24 패시트 바이오테크 코포레이션 Ｉｇｇ 항체의 안정한 액상 약학 제형물
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
US7157235B2 (en) 2002-06-17 2007-01-02 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
RU2374241C2 (ru) 2003-05-20 2009-11-27 Новартис Аг N-ацилированные азотсодержащие гетероциклические соединения в качестве лигандов ppar-рецепторов, активируемых пролифератором пероксисомы
TW200526254A (en) 2003-09-19 2005-08-16 Novo Nordisk As Novel GLP-1 derivatives
US20050191668A1 (en) 2004-01-14 2005-09-01 Lubing Zhou Methods of using peroxisome proliferator-activated receptor alpha target genes
PT2441466E (pt) 2004-04-13 2014-09-09 St Vincents Hosp Sydney Agente de inibição de mic-1
US20070207120A1 (en) 2004-04-14 2007-09-06 Sarah Drayton Selective Killing Of Cancer Cells By Induction Of Acetyltransferase Via Tnf-Alpha And Il-6
US8431558B2 (en) 2004-11-01 2013-04-30 The Regents Of The University Of California Compositions and methods for modification of biomolecules
US20090142338A1 (en) * 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
CA2607715C (en) 2005-04-29 2015-11-24 Glaxosmithkline Biologicals S.A. Novel method for preventing or treating m tuberculosis infection
US20110319324A1 (en) 2005-05-27 2011-12-29 Five Prime Therapeutics, Inc. Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
CN101405293B (zh) 2005-11-30 2013-03-13 中裕新药股份有限公司 天冬氨酰基蛋白酶抑制剂基于赖氨酸的前体药物及其制备方法
DK1962886T4 (da) 2005-12-20 2022-05-02 Bristol Myers Squibb Co Stabile proteinformuleringer
CN101002945B (zh) 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
WO2009021293A1 (en) 2007-08-16 2009-02-19 St Vincent's Hospital Sydney Limited Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
WO2009042798A1 (en) 2007-09-26 2009-04-02 Cold Spring Harbor Laboratory Methods for treating fibrosis by modulating cellular senescence
US8420088B2 (en) 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
AU2009233429B2 (en) 2008-03-31 2014-02-13 Ferring B.V. Oxytocin analogues
KR101316159B1 (ko) 2008-10-24 2013-10-15 아이알엠 엘엘씨 생합성적으로 생성된 피롤린-카르복시-리신, 및 피롤린-카르복시-리신 및 피롤리신 잔기의 화학적 유도체화를 통한 부위 특이적 단백질 변형
CN102202681A (zh) * 2008-11-05 2011-09-28 霍夫曼-拉罗奇有限公司 神经肽-2受体(y-2r)激动剂及其用途
EP2209003A1 (en) 2009-01-16 2010-07-21 F. Hoffmann-Roche AG Means and methods for differentiating between fibrosis and cirrhosis
EP2211182A1 (en) 2009-01-16 2010-07-28 Roche Diagnostics GmbH Method for the assessment of severity of liver cirrhosis
EP2261662B1 (en) * 2009-06-10 2014-01-22 Forschungszentrum Borstel Leibniz-Zentrum für Medizin und Biowissenschaften Novel synthetic blocking reagents
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
CA2785834A1 (en) 2010-01-06 2011-07-14 The University Of North Carolina At Chapel Hill Fatty acid derivatives and analogs of drugs
CN101852804B (zh) 2010-03-29 2013-06-12 中国医学科学院病原生物学研究所 Gdf15蛋白的抗体的新用途
CN107235828B (zh) 2010-04-27 2024-06-07 西纳福克斯股份有限公司 稠合的环辛炔化合物及其在无金属点击反应中的应用
BR112012029611A2 (pt) 2010-05-21 2017-07-25 Merrimack Pharmaceuticals Inc proteína de fusão biespecífica, composição farmacêutica, método de tratamento de dano ao tecido em um indivíduo, método de promoção da regeração ou sobrevivência do tecido em um indivíduo e molécula de ácido nucleico
GB201018518D0 (en) 2010-11-03 2010-12-15 Univ Leuven Kath Novel endolysin
CA2832581C (en) * 2011-04-08 2022-08-23 Yumei Xiong Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
EP2696897A2 (en) 2011-04-11 2014-02-19 Yeda Research and Development Co. Ltd. Albumin binding probes and drug conjugates thereof
US9394343B2 (en) 2011-07-05 2016-07-19 The Regents Of The University Of California Appetite stimulating protein
WO2013027191A1 (en) 2011-08-25 2013-02-28 Novartis Ag Methods and compositions using fgf23 fusion polypeptides
BR112014018575A2 (pt) 2012-01-26 2017-07-04 Amgen Inc polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
MX366864B (es) 2012-02-27 2019-07-26 Amunix Operating Inc Composiciones de conjugados de xten y métodos para realizarlas.
WO2013148117A1 (en) 2012-03-27 2013-10-03 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
US8921307B2 (en) 2012-11-20 2014-12-30 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure
AU2013350802B2 (en) 2012-11-30 2016-07-14 Novartis Ag Methods for making conjugates from disulfide-containing proteins
MY176398A (en) 2012-12-21 2020-08-05 Hoffmann La Roche Peptides as oxytocin agonists
CA2896076C (en) 2012-12-21 2022-12-06 Aveo Pharmaceuticals, Inc. Anti-gdf15 antibodies
RU2704285C2 (ru) 2013-01-30 2019-10-25 Нгм Байофармасьютикалз, Инк. Композиции и способы применения для лечения метаболических расстройств
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
LT2981822T (lt) 2013-05-06 2020-12-28 Scholar Rock, Inc. Kompozicijos ir būdai, skirti augimo faktoriaus moduliacijai
US20150017166A1 (en) 2013-07-03 2015-01-15 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
CA2918076A1 (en) 2013-07-11 2015-01-15 Novartis Ag Site-specific chemoenzymatic protein modifications
MX2016001020A (es) 2013-07-25 2016-08-03 Novartis Ag Polipeptidos ciclicos para el tratamiento de insuficiencia cardiaca.
EP3024847A1 (en) 2013-07-25 2016-06-01 Novartis AG Disulfide cyclic polypeptides for the treatment of heart failure
US9340582B2 (en) 2013-07-25 2016-05-17 Novartis Ag Bioconjugates of synthetic apelin polypeptides
CN105612173A (zh) 2013-07-25 2016-05-25 诺华股份有限公司 用于治疗心力衰竭的环状apelin衍生物
AU2014296107B2 (en) 2013-07-31 2018-07-26 Amgen Inc. Growth differentiation factor 15 (GDF-15) constructs
EA201691075A1 (ru) 2013-11-26 2016-09-30 Новартис Аг Способы оксимной конъюгации с кетон-модифицированными полипептидами
WO2015120350A2 (en) 2014-02-07 2015-08-13 Effector Therapeutics, Inc. Compositions and methods for treating fibrotic disease
JP6329626B2 (ja) 2014-05-01 2018-05-23 富士フイルム株式会社 赤外線センサ、近赤外線吸収組成物、感光性樹脂組成物、化合物、近赤外線吸収フィルタおよび撮像装置
EP3139957A4 (en) 2014-05-06 2018-04-25 Scholar Rock, Inc. Compositions and methods for growth factor modulation
WO2015179734A1 (en) 2014-05-23 2015-11-26 Novartis Ag Methods for making conjugates from disulfide-containing proteins
EA201790051A1 (ru) 2014-06-20 2017-04-28 Авео Фармасьютикалз, Инк. Лечение хронического заболевания почек и другого нарушения функции почек при помощи модулятора gdf15
EP3157947A1 (en) 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
WO2015200080A1 (en) 2014-06-23 2015-12-30 Novartis Ag Site specific protein modifications
JP6696915B2 (ja) 2014-06-24 2020-05-20 ノヴォ ノルディスク アー／エス Ｍｉｃ−１融合タンパク質及びその使用
CR20170027A (es) 2014-07-30 2017-05-09 Ngm Biopharmaceuticals Inc Composiciones y métodos de uso para tratar trastornos metabólicos
WO2016069925A1 (en) 2014-10-30 2016-05-06 Acceleron Pharma Inc. Methods and compositions using gdf15 polypeptides for increasing red blood cells
TWI703161B (zh) 2014-10-31 2020-09-01 美商Ｎｇｍ生物製藥公司 用於治療代謝病症之組合物及方法
WO2016102580A1 (en) 2014-12-22 2016-06-30 Novo Nordisk A/S Alpha-1-antitrypsin (a1at) fusion proteins and uses thereof
AU2016209968B2 (en) 2015-01-23 2018-11-29 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
SI3280727T1 (sl) 2015-04-06 2021-07-30 Acceleron Pharma Inc. Enoskupinske fuzijske beljakovine receptorjev tipa I in tipa II ter njihova uporaba
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
EP3889171A1 (en) 2015-04-06 2021-10-06 Acceleron Pharma Inc. Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof
WO2017066525A1 (en) 2015-10-14 2017-04-20 The Johns Hopkins University Protein bioconjugation method
JP6946304B2 (ja) 2015-12-22 2021-10-06 ノバルティス アーゲー 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法
EP3184106A1 (en) 2015-12-23 2017-06-28 Sanofi-Aventis Deutschland GmbH Growth differentiation factor 15 as biomarker for metformin
US11105818B2 (en) 2016-01-15 2021-08-31 Novo Nordisk A/S MIC-1 receptor and uses thereof
JP2019510739A (ja) 2016-02-29 2019-04-18 イーライ リリー アンド カンパニー Ｇｆｒａｌ受容体療法
EP3423097A4 (en) 2016-03-04 2019-08-21 NGM Biopharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR MODULATING BODY WEIGHT
KR101727506B1 (ko) 2016-07-14 2017-05-04 충남대학교 산학협력단 Gdf15 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 유효성분으로 함유하는 지방간의 예방 또는 치료용 약학적 조성물
EP3612558A1 (en) 2017-04-20 2020-02-26 Novo Nordisk A/S Methods of purification of albumin fusion proteins
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
US11260108B2 (en) 2017-09-10 2022-03-01 Novo Nordisk A/S MIC-1 and GLP-1 for use in the treatment of obesity
AU2020233876A1 (en) 2019-03-08 2021-09-23 Amgen Inc. Growth differentiation factor 15 combination therapy
WO2021067655A1 (en) 2019-10-04 2021-04-08 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
CN113597434B (zh) 2019-12-31 2022-07-01 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
WO2021211683A2 (en) 2020-04-15 2021-10-21 Theradaptive, Inc. Compositions and methods for targeted therapeutic delivery to bone
WO2022092915A1 (ko) 2020-10-30 2022-05-05 가톨릭대학교 산학협력단 Gdf15를 유효성분으로 함유하는 면역질환의 예방 및 치료용 조성물

Also Published As

Publication number Publication date
MY193993A (en) 2022-11-07
CR20160596A (es) 2017-05-08
TN2016000558A1 (en) 2018-04-04
JP6823696B2 (ja) 2021-02-03
CL2016003281A1 (es) 2017-06-09
IL248990A0 (en) 2017-01-31
JP7051959B2 (ja) 2022-04-11
PE20171095A1 (es) 2017-08-07
CN114133443A (zh) 2022-03-04
UY36186A (es) 2016-01-29
SG11201609704TA (en) 2017-01-27
US10786576B2 (en) 2020-09-29
JO3813B1 (ar) 2021-01-31
MA40278A (fr) 2017-04-26
MX2016017395A (es) 2017-05-01
MX367520B (es) 2019-08-26
JP2022095757A (ja) 2022-06-28
KR102559975B1 (ko) 2023-07-27
KR20230056796A (ko) 2023-04-27
HUE057845T2 (hu) 2022-06-28
EA201692466A1 (ru) 2017-04-28
US10588980B2 (en) 2020-03-17
RS62907B1 (sr) 2022-03-31
ES2905479T3 (es) 2022-04-08
EP3988170A1 (en) 2022-04-27
SI3157571T1 (sl) 2022-04-29
TW202204384A (zh) 2022-02-01
TWI750725B (zh) 2021-12-21
US20240066132A1 (en) 2024-02-29
JP2020203934A (ja) 2020-12-24
IL248990B (en) 2019-09-26
JP2017519024A (ja) 2017-07-13
DK3157571T3 (da) 2022-02-21
LT3157571T (lt) 2022-02-25
WO2015200078A8 (en) 2016-04-14
HRP20220152T1 (hr) 2022-04-15
EP3157571B1 (en) 2021-11-24
PL3157571T3 (pl) 2022-03-28
WO2015200078A1 (en) 2015-12-30
TW201613653A (en) 2016-04-16
AP2016009585A0 (en) 2016-11-30
AU2015280351A1 (en) 2016-12-08
JP2019206563A (ja) 2019-12-05
TW202039004A (zh) 2020-11-01
CU24455B1 (es) 2019-11-04
JP6636959B2 (ja) 2020-01-29
EA039074B1 (ru) 2021-11-30
AU2015280351C1 (en) 2022-11-24
CN114099693A (zh) 2022-03-01
ECSP17004665A (es) 2018-11-30
BR112016028884A2 (pt) 2017-10-31
PH12016502294B1 (en) 2017-02-13
KR20170020878A (ko) 2017-02-24
HK1232160A1 (zh) 2018-01-05
CN107073130B (zh) 2021-11-16
US20160030585A1 (en) 2016-02-04
CA2953480A1 (en) 2015-12-30
CY1125006T1 (el) 2023-01-05
SG10201912965TA (en) 2020-02-27
PT3157571T (pt) 2022-02-14
EP3157571A1 (en) 2017-04-26
CN107073130A (zh) 2017-08-18
US20210000964A1 (en) 2021-01-07
US11752211B2 (en) 2023-09-12
CU20160189A7 (es) 2017-04-05
JP2023099133A (ja) 2023-07-11
US20180326079A1 (en) 2018-11-15
AU2015280351B2 (en) 2018-07-05
TWI701048B (zh) 2020-08-11
TWI792596B (zh) 2023-02-11
PH12016502294A1 (en) 2017-02-13

Similar Documents

Publication Publication Date Title
GT201600263A (es) Ácidos grasos novedosos y su uso en la conjugación con biomoléculas
CY1123307T1 (el) Πρωτεϊνες συγχωνευσης fgf21 μακρας δρασης και φαρμακευτικες συνθεσεις που τις περιλαμβανουν
BR112018008805A2 (pt) proteínas de função dupla e composição farmacêutica que compreende a mesma
CO6781465A2 (es) Composición farmacéutica, métodos de tratamiento y usos de la misma
EA202091284A1 (ru) Аналоги инкретина и их применение
BR112017008160A8 (pt) Peptídeo, composição, métodos para tratamento de um paciente ou indivíduo e para tratamento de uma doença metabólica, e, usos de um peptídeo e de uma composição
MX2022009595A (es) Sales de berberina, sales ursodesoxicolicas y combinaciones, metodos de preparacion y aplicacion de las mismas.
CO6410287A2 (es) Composición farmacéutica, forma farmacéutica, procedimiento para su preparación, métodos de tratamiento y usos de la misma
MX359221B (es) Derivados de tienopiridona útiles como activadores de ampk.
EA201300522A1 (ru) Фармацевтические комбинации для лечения метаболических нарушений
NI201200038A (es) Conjugados de niacina y ácidos grasos y sus usos
BR112013027674A2 (pt) "usos de composições de nanopartículas, composições compreendendo as referidas nanopartículas e cateter com uma agulha".
ECSP10010106A (es) Trans-clomifeno para el síndrome metabólico
PE20151595A1 (es) Compuestos de pirazol-amida y sus usos farmaceuticos
ES2445846R1 (es) Una composición de combinación farmacéutica y su uso para preparar un medicamento destinado al tatamiento de la diabetes de tipo l y los trastornos metabólicos
PE20171622A1 (es) Formulacion de relacion fija de insulina glargina/lixisenatida
JP2017509628A5 (es)
CL2009001366A1 (es) Compuestos derivados de heterociclil-sulfonamidas con un grupo de cabeza de heterociclo y oxadiazolona; composicion farmaceutica y su proceso de preparacion; y su uso para el tratamiento y/o prevencion de trastornos del metabolismo de acidos grasos y de la glucosa, tal como diabetes mellitus, resistencia a la insulina, dislipidemias, entre otras.
UY36098A (es) Compuesto 1,1?-adipoilbis(pirrolidina-2-carboxilato) de (2r,2?r)-bis(((((tetrahidro-2h-piran-4- il)oxi)carbonil)oxi)metilo), para el tratamiento de la amiloidosis sistémica.
ATE534382T1 (de) Pharmazeutische zusammensetzungen von mit zuckeralkoholen zusammen mikronisiertem entacapon
AR100939A1 (es) Ácidos grasos y su uso en la conjugación con biomoléculas con acción terapéutica
WO2010088899A3 (de) Ein l-ribozym enthaltende pharmazeutische zusammensetzung zur behandlung von nebenwirkungen durch gabe von spiegelmeren
EP4233877A3 (en) Compositions and methods for increasing athletic performance
EA202192269A3 (ru) Жирные кислоты и их применение для конъюгации с биомолекулами
PE20070749A1 (es) Uso de paliperidona para el tratamiento de un trastorno mental en un paciente psiquiatrico con funcionamiento hepatico reducido